CN
Genecast presented 2 studies at WCLC 2024，including 2 oral presentations：
| ID | Title |
| MA15.04 | MRD Predicts clinical outcomes of Patients with Early-Stage EGFR-Mutant NSCLc: A Post-Hoc Biomarker Analyses Of EVIDENCE |
| P1.03D.01 | Efficacy and biomarker analysis of neoadjuvant toripalimab plus chemotherapy in resectable stage IIB-IIIB non-small cell lung cancer (RENAISSANCE study) |
#02-01/02, The Kendall, 50 Science Park Road. Singapore Science Park 2, Singapore 117406
Tel: +65 6047 0252 ; Email: info@genecast.com.sg
Copyright © 2014-2026 Genecast Group Inc. | Privacy Policy
